Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

Journal of Clinical Pharmacology

Volumn 55, Issue 8, 2015, Pages 866-874

  Wade, Janet R ^a   Parker, Gerry ^b   Kosutic, Gordana ^c   Feagen, Brian G ^d   Sandborn, William J ^e   Laveille, Christian ^a   Oliver, Ruth ^b  

^a Exprimo NV   (Belgium)

^b UCB PHARMA   (Belgium)

^c UCB   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anti TNF; certolizumab pegol; covariates; Crohn's disease; NONMEM

Indexed keywords

ALBUMIN; BOVINE SERUM ALBUMIN; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; BODY SURFACE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; FEMALE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; POPULATION PHARMACOKINETICS; VERY ELDERLY; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; BLOOD; BODY WEIGHT; IMMUNOLOGY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; BODY SURFACE AREA; BODY WEIGHT; C-REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; YOUNG ADULT;

EID: 84936132902     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.491     Document Type: Article

References (18)

1. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OØ, Brynskov J,. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009; 44 (7): 774-781.
2. Ordás I, Mould DR, Feagan BG, Sandborn WJ,. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Phar Ther. 2012; 91 (4): 635-646.
3. Xu Z, Seitz K, Fasanmade A, et al., Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol. 2008; 48 (6): 681-695.
4. Fasanmade AA, Adedokun OJ, Ford J, et al., Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009; 65 (12): 1211-1228.
5. Schreiber S, Rutgeerts P, Fedorak RN, et al., CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005; 129 (3): 807-818. Erratum in: Gastroenterology. 2005;129(5):1808. Dosage error in article text.
6. Sandborn WJ, Feagan BG, Stoinov S, et al., PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357 (3): 228-238.
7. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al., PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357 (3): 239-250. Erratum in: N Engl J Med. 2007;357(13):1357.
8. Sandborn WJ, Abreu MT, D'Haens G, et al., Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010; 8 (8): 688-695.
9. Colombel JF, Sandborn WJ, Allez M, et al., Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014; 12 (3): 423-431.
10. Sandborn WJ, Schreiber S, Feagan BG, et al., Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011; 9 (8): 670-678.
11. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, eds. NONMEM Users Guides. 1989-2011. Ellicott City, MD: Icon Development Solutions.
12. Montgomery DC, Peck EA,. Introduction to Linear Regression Analysis. New York: Wiley 1982 301-302.
13. Lindbom L, Pihlgren P, Jonsson EN,. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NON MEM. Comput Methods Programs Biomed. 2005; 79 (3): 241-257.
14. Lindbom L, Ribbing J, Jonsson EN,. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004; 75 (2): 85-94.
15. Fasanmade AA, Adedokun OJ, Blank M, Zhu H, Davis HM,. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011; 33 (7): 946-964.
16. Moshage HJ, Janseen AM, Franssen JH, Hafkenscheid JC, Yap SH,. Study of the molecular mechansim of mecreased liver synthesis of albumin inflammation. J Clin Invest. 1987; 79 (6): 1635-1641.
17. Magro F, Rodrigues-Pinto E, Santos-Antunes J, et al., High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.J Crohns Colitis. 2014; 8 (2): 129-136.
18. Reinisch W, Wang Y, Oddens BJ, Link R,. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012; 35 (5): 568-576.